Targeted therapy in renal cell carcinoma
暂无分享,去创建一个
[1] D. Mukhopadhyay,et al. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. , 2001, Cancer research.
[2] T. Tammela,et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Hidalgo. New target, new drug, old paradigm. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[5] J. Hainsworth,et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Bukowski,et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .
[7] C. J. Barnes,et al. Biology of the epidermal growth factor receptor family. , 2004, Cancer treatment and research.
[8] Molecular genetics of renal cell carcinoma. , 1996, Seminars in urologic oncology.
[9] D. Hicklin,et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.
[10] R. Figlin,et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Hainsworth,et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial , 2005 .
[12] R. Klausner,et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. , 1996, Biochimica et biophysica acta.
[13] R. Motzer,et al. Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma , 2003, Investigational New Drugs.
[14] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[15] J. Hennig,et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. , 2002, Cancer research.
[16] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[17] N. Sonenberg,et al. Upstream and downstream of mTOR. , 2004, Genes & development.
[18] D. Eberhard,et al. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. , 2000, Cancer research.
[19] K. Pandya,et al. Interferon α-2b and megestrol acetate in the treatment of advanced renal cell carcinoma: A phase II study , 1998 .
[20] R. Motzer,et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) , 2005 .
[21] W. Linehan,et al. A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] W. Kaelin. The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer , 2004, Clinical Cancer Research.
[23] S. Liou,et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Hennig,et al. PTK 787 / ZK 222584 , a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor , Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging 1 , 2002 .
[25] J. Hainsworth,et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial , 2005 .
[26] G C Vignoli,et al. Molecular genetics of renal cell carcinoma. , 1997, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[27] J. Dutcher. Interleukin-2 based therapy for kidney cancer. , 2003, Cancer treatment and research.
[28] Kun-Liang Guan,et al. Mechanisms of regulating the Raf kinase family. , 2003, Cellular signalling.
[29] Shile Huang,et al. Rapamycins: Mechanisms of Action and Cellular Resistance , 2003, Cancer biology & therapy.
[30] M. Labopin,et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.